Mara Aspinall is a healthcare industry pioneer and visionary who has built successful companies in all facets of the diagnostics industry. Mara also has extensive experience in the genetic disease industry. Mara was the President of Genzyme Genetics, the leading provider of genetic testing in the oncology and reproductive markets. Under Aspinall’s leadership, Genzyme Genetics set the industry standard for quality while growing at unprecedented to pace to become one of the world’s largest diagnostic labs. During her tenure as President and CEO of Ventana Medical Systems, Mara led the company to new financial success while launching several dozen new products and establishing itself as the industry’ leading developer and manufacturer of oncology companion diagnostics.
In addition to leading commercial organizations, Mara has led numerous educational initiatives in life sciences, including the creation of the School of Biomedical Diagnostics at Arizona State University, the first school in the world dedicated to diagnostics as an independent discipline. She was an active member of the Secretary of Health and Human Services committee on Genetics, Health and Society (SACGHS) under both the Bush and Obama administrations. Aspinall is a Director of Safeguard Scientific, (NYSE: SFE) a company providing growth capital for innovative healthcare and technology companies and Castle Biosciences.
Mara started her business career at the strategic consulting firm Bain & Company. She holds an MBA from Harvard Business School and a BA in International Relations from Tufts University.
Anne Morriss has an intimate understanding of the urgent need for better genetic information. After using a sperm donor, Anne gave birth to a son with a rare genetic condition that could have been prevented with GenePeeks technology.
Anne received her BA in American Studies from Brown University and an MBA from Harvard Business School. She has helped launch and grow multiple technology companies, with a focus on expanding entrepreneurship in developing economies. Anne served as a senior advisor with the OTF Group, founded the Concire Leadership Institute, and is the best-selling co-author of Uncommon Service: How to Win By Putting Customers at the Core of Your Business (Harvard Business Review Press).
Anne has appeared on 60 Minutes and CBS This Morning to discuss GenePeeks and its mission to protect future generations from disease. She is regularly invited to write and speak on the intersection of leadership, service and innovation. Anne is a frequent contributor to Harvard Business Review and has been featured in publications ranging from BBC News to the Boston Globe for her vision and impact as Co-Founder and CEO of GenePeeks.
Lee Silver holds a PhD from Harvard University and is a Princeton University professor emeritus of molecular biology. He has been elected a lifetime fellow of the American Association for the Advancement of Science and has received a National Institutes of Health MERIT award for outstanding research in genetics. Lee was a member of the New Jersey Bioethics Commission Task Force, and he has testified on reproductive and genetic technologies before U.S. Congressional and New York State Senate committees.
Lee has published over 200 research articles on genetics and computational modeling, as well as two of the leading academic genetic textbooks (Mouse Genetics: Concepts and Application and Genetics: From Genes to Genomes) and two popular science books (Challenging Nature and Remaking Eden). His thought leadership has been showcased on 60 Minutes, CBS This Morning, The Charlie Rose Show, 20/20, PBS, NBC, ABC News, Nightline, and NPR programs such as Intelligence Squared, OnPoint, and Radiolab.
Lee is the lead inventor on two issued patents (U.S. 8,620,594 and U.S. 8,895,629) for his method of generating a hypothetical progeny genome, which is the basis of the GenePeeks technology.
Over the course of his career, Matt Posard has held influential leadership roles at a number of market leading companies including Illumina, Inc., Trovagene, Inc. and Alere, Inc. During his nine years at Illumina, Matt held several key executive positions including senior leadership roles in Marketing, Global Sales, Translational and Consumer Genomics, and New and Emerging Markets. He built and led the team responsible for growing company sales to more than $1 billion in five years, drove global product launches of multiple clinical and consumer genomic applications, and established several new business units where he oversaw Commercial, Product Development, Business Development, Professional Services and Laboratory Operations.
He earned his Bachelor of Arts degree in Quantitative Economics and Decision Science from the University of California, San Diego.
Daniel Geffken has more than 22 years of experience in the life sciences industry, ranging from start-ups to publicly traded companies with $1 billion+ market capitalizations. He has served as COO or CFO of four publicly traded and four privately held companies, in addition to advising a wide range of biotechnology clients on firm-level strategy, operations and finance. Dan has raised more than $700 million in equity and debt securities, including one of the largest PIPEs in biotechnology history.
In addition to serving as the Chief Financial Officer at GenePeeks, Dan is the Founder and Managing Director of Danforth Advisors, a premier life sciences consulting firm. He serves on the Board of Directors for Alcobra Ltd., a biopharmaceutical company that completed its initial public offering in May 2013. He is also the former Co-Chairman of the Association of Bioscience Financial Officers (ABFO) and of the Finance Committee of the Massachusetts Biotechnology Council.
Dan has a B.S. in Economics from The Wharton School, University of Pennsylvania and an M.B.A. from Harvard Business School.